Because Bcc infections are primarily associated with individuals with CGD and CF, it is interesting to compare these two not obviously related genetic diseases. Table summarizes the disease manifestations and defects in phagocyte function associated with CGD and CF.
| Table 1Comparison of disease presentation and phagocyte function in CGD and CF. |
Burkholderia cepacia (previously referred to as
Pseudomonas cepacia) was recognized as an important pathogen in CGD in 1975 (Bottone et al.,
1975). Bcc is now the leading cause of fatality from bacterial infections in CGD patients (Winkelstein et al.,
2000). CGD is a genetic disorder caused by the inactivation of the phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex. Because of this defect, some cells (neutrophils, mononuclear cells, macrophages, and eosinophils) in CGD patients are unable to produce reactive oxygen species (ROS), which results in ineffective clearance of some pathogens. These patients present with recurrent bacterial and fungal infections, which is frequently accompanied by uncontrolled inflammation and granuloma formation. The rate of incidence in the United States is 1/200,000 live births, or at least 20 patients per year (Holland,
2010).
Chronic granulomatous disease can be caused by mutations in any of the four components of NADPH oxidase. Flavocytochrome
b558 is the catalytic center of the complex, and is a heterodimer composed of p22
phox and gp91
phox. It is contained on the membrane of specific granules and is incorporated into the phagosome membrane upon fusion (Segal,
2005). It provides a channel for electrons to be transferred through from NADPH in the cytosol to oxygen that is contained in the phagosome (Segal,
2005). The complex also contains two cytosolic components: p67
phox and p47
phox (Zarember and Malech,
2011). These cytoplasmic components are essential for stabilizing flavocytochrome
b558 and facilitating the transfer of electrons. A defect in any one of these four components leads to inactivation of the complex and an inability to produce ROS. X-linked recessive CGD is caused by defects in gp91
phox. Autosomal recessive CGD is caused by defects in p47
phox, p67
phox, or p22
phox. Approximately 65% of CGD cases are X-linked (defects in gp91
phox), 25% of cases are due to defects in p47
phox, and the rest are split evenly between defects in p67
phox and p22
phox (Holland,
2010). There are two other genetic disorders with similar presentations to CGD that are not caused by mutations in NADPH oxidase components. Inhibitory mutations in Rac or deficiencies of glucose-6-phosphate dehydrogenase can also result in an inability to produce ROS (Johnston,
2001).
Overall mortality for CGD patients is around 2–5% per year, but morbidity remains a major issue for these patients and their families, as most patients have at least one severe infection every 3–4

years (Winkelstein et al.,
2000; Marciano et al.,
2004). In the initial cases of CGD diagnosed between 1957 and 1976,
Staphylococcus was the most common infectious agent, followed by the common enteric pathogens
Klebsiella species and
Escherichia coli (Johnston,
2001). Now
Aspergillus species are the most common causative infectious agents, followed by Bcc and
Staphylococcus aureus (Winkelstein et al.,
2000). The most common presentations of infection include pneumonia, infectious dermatitis, and recurrent/severe abscess formation beneath the skin and in organs (Winkelstein et al.,
2000). Other symptoms have been described that are not caused directly by infection, including enteritis/colitis, discoid lupus, and chorioretinitis (Goldblatt et al.,
1999; Segal et al.,
2000; Winkelstein et al.,
2000). The treatment regimen for these patients includes interferon-γ, antibacterial prophylaxis, and antifungal prophylaxis. Prophylactic treatment usually includes trimethoprim–sulfamethoxazole and itraconazole (Seger,
2008). Bone marrow transplantation can cure the disease if a histocompatible donor is available, which is not an option for most patients. As with other monogenetic diseases, gene therapy has the potential to be an effective curative treatment for CGD, however, to date, clinical trials have not been successful. The promise and problems associated with this approach have been recently reviewed (Grez et al.,
2011).
Cystic fibrosis is caused by mutations in the CF transmembrane conductance regulator (CFTR), which functions as an ion channel. This defect results in the accumulation of mucus on epithelial surfaces, which contributes to ineffective mucociliary clearance in the lungs. CF is one of the most common inherited genetic diseases in the world with an annual frequency of approximately 1/3,000 live births (Hayes et al.,
2011). In fact, one out of every 25 Caucasians is a heterozygous carrier of a mutated CFTR gene (Sheppard and Nicholson,
2002). The airway in CF patients is chronically colonized with potentially pathogenic bacteria, specifically
Pseudomonas aeruginosa, S. aureus, and
Haemophilus influenzae. Colonization and frequent infection of the CF airway leads to an excessive neutrophil (polymorphonuclear leukocyte, PMN) driven inflammatory response, which results in host tissue damage (McElvaney et al.,
1992; Birrer et al.,
1994). These patients experience recurrent respiratory infections and chronic lung inflammation that eventually culminates in respiratory failure (Dinwiddie,
2000). Pulmonary inflammation in CF is associated with high levels of inflammatory cytokines (IL-8, IL-6, TNF-alpha, and leukotriene B
4), reduced levels of anti-inflammatory cytokines and antiproteases, and a rapid and substantial influx of PMNs (Rowe et al.,
2005).
Burkholderia cepacia complex infections in both the CGD and CF patient populations initially present as a respiratory tract infection. An interesting distinction between infections in these two patient populations is the clinical presentation of this infection. In CF, pulmonary infection with Bcc generally causes endobronchial disease, and diagnosis is made by identification of bacteria in the sputum. In CGD, Bcc lung infection results in a pneumonic process associated with nodular infiltrates and diagnosis requires isolation following lung biopsy. Antibiotic treatment is generally able to clear Bcc in CGD, although recurrent re-infections do occur. In CF, Bcc infections are usually seen in older patients that are already chronically colonized with other CF pathogens, notably
P. aeruginosa (Sheppard and Nicholson,
2002). According to the 2009 Cystic Fibrosis Foundation Registry Report, about 2.7% of CF patients are infected with Bcc, and these infections are associated with earlier fatality than non-Bcc-infected patients. Potentially due to the chronic nature of Bcc infections in CF and the sustained presence of the microbial community in the form of biofilms in the CF lung, Bcc isolates associated with CF show a higher degree of antibiotic resistance than Bcc isolates from CGD infections (Greenberg et al.,
2009). Bcc infections in CF patients can result in a severe, necrotizing pneumonia, referred to as “cepacia syndrome,” that is not observed in Bcc infections in CGD patients. However, Bcc infections in CGD patients can become invasive and result in septicemia.
Chronic granulomatous disease and CF are both rare genetic diseases and, while infections by Bcc are prominent in these populations, Bcc infections are still relatively infrequent. Studies investigating Bcc virulence in CGD and CF aim to decrease morbidity and mortality in these patient populations, but they can also increase our understanding of how healthy individuals are able to fight off these rare infections. Since Bcc infections are very uncommon in immunocompetent individuals, the normal host immune response must be able to efficiently remove these pathogens, and the immune response or environment in CGD and CF, as well as other immunocompromised patients, would appear to be defective in this clearance. It is the investigation into the distinction between these normal and susceptible hosts that gives insight into normal and defective immune function in bacterial infections. Previous studies investigating CGD and other rare genetic diseases have contributed greatly to knowledge in the field on normal phagocyte function and bacteria–phagocyte interactions (Quie et al.,
1967; Root et al.,
1972; Lekstrom-Himes and Gallin,
2000). A better understanding of the infectious processes in patients with rare genetic defects in phagocyte function contributes to current knowledge on how normal, healthy individuals resist infections.